Status:
TERMINATED
Bicillin L-A vs Placebo for the Treatment of Chronic, Plaque-Type Psoriasis Unresponsive to Topical Medications
Lead Sponsor:
University of Tennessee
Conditions:
Psoriasis
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the efficacy for Bicillin L-A, administered intramuscularly in a dose of 2.4 million units every three (3) weeks, for the treatment of chronic, plaque-type ps...
Detailed Description
Psoriasis is a chronic, inflammatory skin disorder most commonly manifested by well-demarcated, erythematous and/or scaling plaques on the elbows, knees, scalp, and trunk. Psoriasis is a common diseas...
Eligibility Criteria
Inclusion
- Male or female between 18 and 50 years of age (with onset before age 40)
- Presence of chronic plaque type psoriasis unresponsive to treatment with topical preparations and extensive enough to consider appropriateness of systemic therapy
- Guttate forms of psoriasis
- Non-responsive to treatment or worsening of the pre-existing psoriasis
- With the exception of their skin disease , in good general state of health based on a complete medical history, blood test and urine analysis.
- Females must have negative urine pregnancy test and willing to take additional measures to keep from becoming pregnant during the course of the study
- No systemic prescription medication to control psoriasis within past 30 days
- Free of any topical antipsoriatic preparation for the duration of the study with the exception of emollients and moisturizers
Exclusion
- Pustular forms of psoriasis, either localized or generalized
- Generalized Erythrodermic psoriasis
- Only palmoplantar psoriasis
- Only scalp psoriasis
- Only nail psoriasis
- Only inverse psoriasis
- Diabetes or impaired glucose tolerance
- History of recurrent yeast infections
- History of hypersensitivity to Penicillin
- History of severe adverse drug reactions
- Pregnancy
- Lactation
- HIV/AIDS
- History of renal disease
- History of liver disease
- History or presence of alcohol and/or drug dependence or abuse
- History of significant psychiatric illness
- History of allergy, asthma, allergic rhinitis, or urticaria subjects in other research trials, at least 30 days prior to the beginning of this study
Key Trial Info
Start Date :
January 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2009
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT00427609
Start Date
January 1 2007
End Date
November 1 2009
Last Update
April 21 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Tennessee Health Science Center
Memphis, Tennessee, United States, 38163